Patents Assigned to Glaxo Wellcome Inc.
  • Stabilized pharmaceutical
    Patent number: 5763493
    Abstract: This application discloses a method of inhibiting degradation of the antidepressant bupropion hydrochloride in a solid pharmaceutical formulation, so that the pharmaceutical formulation will maintain at least 80% of its initial bupropion potency after one year.
    Type: Grant
    Filed: June 21, 1996
    Date of Patent: June 9, 1998
    Assignee: Glaxo Wellcome Inc.
    Inventors: Michael D. Ruff, Sanvasi R. Kalidindi, Joel Elmore Sutton, Jr.
  • Arylmorpholine preparation and use
    Patent number: 5760224
    Abstract: Novel morpholines of formula (I) and their salts, wherein R and R1 are each either hydrogen or fluorine and R2 is hydrogen or methyl. The compounds have a variety of uses in human medicine, in particular in the treatment of mental disorders such as depression.
    Type: Grant
    Filed: March 28, 1997
    Date of Patent: June 2, 1998
    Assignee: Glaxo Wellcome Inc.
    Inventors: Nariman Bomanshaw Mehta, Grady Evan Boswell, James Leroy Kelley
  • Therapeutic methods for using ARA-G derivatives
    Patent number: 5747472
    Abstract: 6-Alkoxy derivatives of Ara-G, and pharmaceutically acceptable esters thereof, are described as being useful in tumour therapy. Novel pharmaceutically acceptable esters, their preparation and pharmaceutical formulations containing them are also disclosed.
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: May 5, 1998
    Assignee: Glaxo Wellcome Inc.
    Inventors: Thomas Anthony Krenitsky, Devron Randolph Averett, George Walter Koszalka, Gerald Wolberg
  • CCK or gastrin modulating 5-heterocyclic-1, 5 benzodiazepines
    Patent number: 5739129
    Abstract: Compounds of general formula (I) and physiologically salts thereof, processes for their preparation and their use as modulators of the effects of gastrin and CCK.
    Type: Grant
    Filed: October 11, 1996
    Date of Patent: April 14, 1998
    Assignee: Glaxo Wellcome Inc.
    Inventors: Christopher Joseph Aquino, Elizabeth Ellen Sugg, Jerzy Ryszard Szewczyk
  • Use of azathioprine to treat crohn's disease
    Patent number: 5733915
    Abstract: A therapeutic method for the treatment of Crohn's disease is provided, comprising administering to a patient in need of said treatment an intravenous dose of azathioprine or a pharmaceutically acceptable derivative thereof.
    Type: Grant
    Filed: March 30, 1995
    Date of Patent: March 31, 1998
    Assignee: Glaxo Wellcome Inc.
    Inventor: William J. Sandborn
  • Stabilized pharmaceutical composition containing bupropion
    Patent number: 5731000
    Abstract: This application discloses a method of inhibiting degradation of the antidepressant bupropion hydrochloride in a solid pharmaceutical formulation, so that the pharmaceutical formulation will maintain at least 80% of its initial bupropion potency after one year.
    Type: Grant
    Filed: March 22, 1996
    Date of Patent: March 24, 1998
    Assignee: Glaxo Wellcome Inc.
    Inventors: Michael David Ruff, Sanyasi Raju Kalidindi, Joel Elmore Sutton, Jr.
  • Therapeutic benzonitriles
    Patent number: 5723452
    Abstract: The present invention relates to novel compounds of formula (I): ##STR1## or a physiologically functional derivative thereof, pharmaceutical formulations containing them, processes for their preparation and their use in therapy for the prophylaxis or treatment of HIV infection or inflammation are disclosed.
    Type: Grant
    Filed: August 21, 1996
    Date of Patent: March 3, 1998
    Assignee: Glaxo Wellcome Inc.
    Inventor: Joseph Howing Chan
  • Hypolipidaemic compounds
    Patent number: 5723458
    Abstract: The invention provides novel 1,4-benzothiazepine compounds substituted with hydroxy or a group containing hydroxy, compositions comprising such compounds and their use in the treatment or prophylaxis of treating clinical conditions in which inhibition of bile acid uptake is indicated, for example, hyperlipidemia and atherosclerosis.
    Type: Grant
    Filed: August 15, 1995
    Date of Patent: March 3, 1998
    Assignee: Glaxo Wellcome Inc.
    Inventors: Lawrence Edward Brieaddy, Gordon Lewis Hodgson, Jr.
  • Amide derivatives and their therapeutic use
    Patent number: 5719186
    Abstract: Novel carbocyclic amides together with their salts, solvates and physiologically active derivatives which have a number of uses in medicine, in particular as central muscle relaxants, and in the treatment or prophylaxis of anxiety, inflammation, arthritis and pain.
    Type: Grant
    Filed: November 8, 1996
    Date of Patent: February 17, 1998
    Assignee: Glaxo Wellcome Inc.
    Inventors: Barrett Randoph Cooper, James Leroy Kelley, David Lee Musso, Jeffrey Leaman Selph
  • Use of 3,5-diamino-6-(2,3-dichlororophenyl) -1,2,4-triazine for the treatment of pain and oedema
    Patent number: 5712277
    Abstract: The present invention relates to the use of 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine and its pharmaceutically and veterinarily acceptable acid addition salts in therapy.
    Type: Grant
    Filed: July 15, 1996
    Date of Patent: January 27, 1998
    Assignee: Glaxo Wellcome Inc.
    Inventors: Meire Nakamura-Craig, Michael John Leach
  • 2-(n-alkylpiperazino or morpholino)-4-amino-5-aryl-pyrimidines
    Patent number: 5712276
    Abstract: A class of substituted phenylpyrimidine compounds are disclosed which are potent inhibitors of the excitatory amino acid, glutamate. Such compounds are useful in the treatment or prevention of a range of CNS disorders including cerebral ischaemic damage and epilepsy.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: January 27, 1998
    Assignee: Glaxo Wellcome Inc.
    Inventors: Alistair Ainslie Miller, Malcolm Stuart Nobbs, Richard Martin Hyde, Michael John Leach
  • Substituted 6-azaandrostenones
    Patent number: 5708001
    Abstract: The present invention relates to certain substituted 17.beta.-substituted carbonyl-6-azaandrost-4-en-3-ones of formula (I), wherein R.sup.1 and R.sup.2 i) are independently hydrogen or lower alkyl and the bond between the carbons bearing R.sup.1 and R.sup.2 is a single or a double bond, or ii) taken together are a --CH.sub.2 -- group forming a cyclopropane ring, and the bond between the carbons bearing R.sup.1 and R.sup.2 is a single bond; R.sup.3 is preferably hydrogen, halogen or lower alkyl, R.sup.4 is preferably hydrogen or lower alkyl, X is preferably CH.sub.2, Y is preferably hydrogen and Z is preferably CONR.sup.14 R.sup.15 and R.sup.14 and R.sup.15 are a variety of organic groups, and pharmaceutically acceptable salts thereof, preparation, medical use and pharmaceutical formulations.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 13, 1998
    Assignee: Glaxo Wellcome Inc.
    Inventors: Robert Carl Andrews, Cynthia Markert Cribbs, Stephen Vernon Frye, Curt Dale Haffner, Patrick Reed Maloney
  • Amide derivatives and their therapeutic use
    Patent number: 5708033
    Abstract: A compound of formula (I), wherein R.sup.1 and R.sup.2 are independently selected from chloro, fluoro, bromo, C.sub.1-6 alkyl, C.sub.1-6 alkoxy or C.sub.1-6 haloalkyl provided that both R.sup.1 and R.sup.2 are not fluoro; R.sup.3 and R.sup.4 are independently selected from hydrogen and C.sub.1-6 alkyl, and pharmaceutically acceptable salts, solvates or physiologically functional derivatives thereof, their use in medicine, particularly the phrophylaxis or treatment of conditions associated with inflammation, arthritis, or pain, pharmaceutical compositions comprising them, and processes for their preparation are disclosed.
    Type: Grant
    Filed: November 8, 1996
    Date of Patent: January 13, 1998
    Assignee: Glaxo Wellcome Inc.
    Inventors: James Leroy Kelley, David Lee Musso
  • Fusion proteins
    Patent number: 5700680
    Abstract: A DNA sequence encoding a fusion protein comprising influenza virus HA, at a site of which normally occupied by a natural antigenic epitope thereof a different antigenic epitope is provided, is incorporated in a vector which is capable of expressing the fusion protein when provided in a eucaryotic host. When in the form of a viral vector such as a recombinant vaccinia virus, the vector can be used as a vaccine. Alternatively, the fusion protein expressed by the host can be recovered and provided as a vaccine.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: December 23, 1997
    Assignee: Glaxo Wellcome Inc.
    Inventors: Susan Elizabeth Newton, Berwyn Ewart Clarke
  • Therapy pillow useful for treating gastroesophageal reflux disease (gerd) and other applications
    Patent number: 5697112
    Abstract: A therapy pillow comprising a wedge-shaped resilient foam element having a planar recess in the medial portion of the top surface thereof. A flexible plastic container adapted to be sealingly filled with a fluid snugly fits into the planar recess of the foam element so as to be substantially coplanar with the top surface thereof when filled with a suitable fluid such as water.
    Type: Grant
    Filed: November 8, 1996
    Date of Patent: December 16, 1997
    Assignee: Glaxo Wellcome Inc.
    Inventors: Barbara J. Colavito, Pieter Muntendam
  • Water-dispersible tablets
    Patent number: 5698226
    Abstract: A water-dispersible tablet comprises an active compound such as acyclovir or lamotrigine and a dispersing agent. The dispersing agent is a swellable clay such as a smectite, e.g. Veegum F or bentonite, and is generally present within the granules of the tablet to provide a tablet which is capable of dispersing in water within 3 minutes to provide a dispersion which will pass through a 710 .mu.m sieve. The tablet can be optionally film-coated in which case the dispersion time is less than 5 minutes.
    Type: Grant
    Filed: June 6, 1996
    Date of Patent: December 16, 1997
    Assignee: Glaxo Wellcome Inc.
    Inventor: Krystyna Elzbieta Fielden
  • Monoclonal antibodies for inducing tolerance
    Patent number: 5690933
    Abstract: Tolerance to an antigen is induced in a subject by administering a non-depleting CD4 monoclonal antibody and a non-depleting CD8 monoclonal antibody. Tolerance to the antigen can be induced under cover of these antibodies. A depleting CD4 monoclonal antibody and/or a depicting CD8 monoclonal antibody may be administered prior to the non-depleting antibodies.
    Type: Grant
    Filed: August 12, 1994
    Date of Patent: November 25, 1997
    Assignee: Glaxo Wellcome Inc.
    Inventors: Stephen Paul Cobbold, Herman Waldmann
  • Expression of recombinant proteins in attenuated bacteria
    Patent number: 5683700
    Abstract: The invention concerns a method of prophylactically treating a host against infection by a microorganism, which method comprises administering to the host an attenuated Salmonella bacterium which contains a nirB promoter operably linked to a DNA sequence encoding a heterologous protein. The heterologous protein is expressed in the host and induces in the host an immune response against the microorganism.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: November 4, 1997
    Assignee: Glaxo Wellcome Inc.
    Inventors: Ian George Charles, Steven Neville Chatfield, Neil Fraser Fairweather
  • Treatment of human viral infections
    Patent number: 5683990
    Abstract: Treatment of AIDS or humans carrying or infected with the AIDS virus or having antibodies to the AIDS virus is disclosed using the compound 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof. Also disclosed is the use of the 5'-mono-, di- and triphosphate of 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof for the same purpose. Additionally, there is disclosed the treatment of Kaposi's sarcoma with 3'-azido-3'-deoxythymidine (AZT) and the synergistic activity in the treatment of humans infected with HTLV-III of AZT and interferon as well as AZT and acyclovir and AZT and 2-amino-9-(2-hydroxyethoxymethyl)purine or an ester thereof.
    Type: Grant
    Filed: August 21, 1986
    Date of Patent: November 4, 1997
    Assignee: Glaxo Wellcome Inc.
    Inventors: Janet Litster Rideout, David Walter Barry, Sandra Nusinoff Lehrman, Martha Heider St. Clair, Phillip Allen Furman
  • Pharmacologically active CNS compounds
    Patent number: 5684005
    Abstract: A class of substituted phenylpyrimidine compounds are disclosed which are potent inhibitors of the excitatory amino acid, glutamate. Such compounds are useful in the treatment or prevention of a range of CNS disorders including cerebral ischaemic damage and epilepsy.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: November 4, 1997
    Assignee: Glaxo Wellcome Inc.
    Inventors: Alistair Ainslie Miller, Malcolm Stuart Nobbs, Richard Martin Hyde, Michael John Leach